[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genitourinary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genitourinary-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,73,110,135,164,189,214,237,269,289,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100433365","a-multi-center-natural-history-of-urothelial-cancer-and-rare-genitourinary-tract-malignancies-100433365",false,"NCT04923178","A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies","* INCLUSION CRITERIA:\n* Participants must have histologically or cytologically confirmed urothelial or rare genitourinary cancer including but not limited to the following: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; any testicular cancer, sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, testicular Sertoli or Leydig cell tumors. Any genitourinary cancer can be included at the principal investigator's discretion.\n* Age \\>=18 years.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-None","ALL","18 Years",{"count":18,"type":19},1100,"ESTIMATED","OBSERVATIONAL","Background:\n\nTumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissue banks. This makes it hard for researchers to determine standards of care. Researchers want to learn more about common and rare GU tumors.\n\nObjective:\n\nTo learn more about urinary tract cancers.\n\nEligibility:\n\nPeople ages 18 and older with urinary tract or GU cancer such as bladder, kidney, testicular, prostate, penis, or neuroendocrine cancer.\n\nDesign:\n\nParticipants will be screened with questions about their medical history. Their medical records will be reviewed.\n\nParticipants will have a physical exam. They will give blood and urine samples. They will complete a survey about their family cancer history. Clinical photographs will be taken to document skin lesions.\n\nParticipants may have imaging scans of their chest, abdomen, and pelvis. They may have a contrast agent injected into their arm.\n\nParticipants will get recommendations about how to best manage and treat their cancer. They can ask as many questions as they would like.\n\nParticipants will provide existing tumor samples if available. They may have optional tumor biopsies up to twice a year. For needle biopsies, the biopsy area will be numbed and they will get a sedative. A needle will be inserted through their skin to collect a tumor sample. For skin biopsies, their skin will be numbed. A small circle of skin will be removed.\n\nSome blood and tumor samples may be used for genetic tests.\n\nParticipants will have frequent follow-up visits. If they cannot visit NIH, their home doctor will be contacted. They will be followed on this study for life....",[23,24,25,26,27],"Urothelial Cancer","Bladder Cancer","Genitourinary Cancer","Urogenital Neoplasms","Urogenital Cancer",[29,30,31,32,33,34],"bladder\u002Furachal adenocarcinoma","renal tumors","penile cancers","small cell neuroendocrine carcinoma of the prostate","Renal Cell Carcinoma","Natural History","RECRUITING","2026-06-04",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2022-10-24",{"date":43,"type":19},"2042-12-01",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100380606","phase-1-bintrafusp-alfa-m7824-and-pds01adc-alone-and-in-combination-with-stereotactic-body-radiation-therapy-sbrt-in-adults-with-metastatic-non-prostate-genitourinary-malignancies-100380606","NCT04235777","Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","A Phase I Study of Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","* INCLUSION CRITERIA:\n* Participants must have histologically or cytologically confirmed diagnosis of a metastatic non-prostate genitourinary tumor.\n* Participants must have metastatic disease defined as new or progressive lesions on cross-sectional imaging. Radiological evaluation should occur within 21 days prior to enrollment.\n* Participants must have evaluable or measurable disease, per RECIST 1.1.\n* Participants in Arms 2 and 3 must have at least one site of disease that is amenable to irradiation (irradiation of up to 4 different sites is permitted)\n* Participants must have at least one measurable site of disease (according to RECIST criteria) that will not be irradiated.\n* Participants may have been previously treated with cytotoxic chemotherapy regimen or targeted agent. Participants may have received any number of prior cytotoxic agents.\n* Participants may have been previously treated with radiation therapy. However, re-irradiation of a previously irradiated site is not permitted unless explicitly discussed with protocol PI and treating radiation oncologist.\n* Participants may have had prior immunomodulating therapy including therapy with a checkpoint inhibitor but excluding prior treatment with M7824 and\u002For PDS01ADC.\n* Participants with locally advanced\u002Fmetastatic clear cell renal cell cancer must have previously received, refused or been ineligible for either axitinib plus pembrolizumab, cabozantinib plus nivolumab, levantinib plus pembrolizumab, axitinib plus avelumab, nivolumab plus ipilumumab, cabozantinib, pazopanib, sunitinib or axitinib.\n* Participants with locally advanced or mestastatic germ cell tumors must have received, refused or been ineligible for prior bleomycin plus etoposide plus cisplatin, etoposide plus cisplatin, etoposide plus ifosfamide plus cisplatin, vinblastine plus ifosfamide plus cisplatin, paclitaxel plus ifosfamide plus cisplatin or autologous hematopoietic cell transplantation.\n* Participants with locally advanced\u002Fmetastatic urothelial cancer must have previously received, refused or been ineligible for platinum chemotherapy and\u002For single agent PD-1\u002FPD-L1 inhibitor.\n* Pre-treatment tissue availability for PD-L1 expression testing is mandatory for enrollment. If tissue is determined to be of insufficient\u002Funsuitable quality\u002Fquantity, a pre-treatment biopsy prior to initiation of study therapy will be required.\n* Male and female participants who are at least 18 years of age on the day of signing the informed consent will be enrolled in the study.\n* ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%)\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes greater than or equal to 2500mcL\n  * absolute neutrophil count greater than or equal to 1500\u002FmcL\n  * platelets greater than or equal to 100,000\u002FmcL\n  * Aspartate Aminotransferase (AST)\u002F Alanine Aminotransferase (ALT) less than or equal to 1.5 X institutional upper limit of normal (ULN)\n  * Hemoglobin (Hgb) greater than or equal to 9g\u002FdL (Packed red blood cells (pRBC) transfusions are allowed to achieve acceptable Hgb)\n* Participants may have mild to moderate hepatic impairment with total bilirubin less than or equal to 3.0 x ULN.\n* For participants with liver involvement in their tumor, we allow the following: AST less than or equal to 5.0 x ULN, ALT less than or equal to 5.0 x ULN, and bilirubin less than or equal to 3.0 x ULN.\n* Calculated Creatinine clearance greater than or equal to 20 mL\u002Fmin (using either CKD-EPY equation)\n* The effects of M7824 and\u002For PDS01ADC on the developing human fetus are unknown. For this reason, individuals of child-bearing potential (IOCBP) and individuals able to father a child must agree to use strict and effective contraception during treatment and after the last dose of M7824 administration - at least 65 days after for IOCBP and 125 days after for individuals able to father a child. Should IOCBPs become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately.\n* Human Immunoodeficiency Virus (HIV)-positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are greater than 350 cells\u002Fmm3 and viral load is undetectable.\n* Participants with previously treated brain or central nervous system (CNS) metastases are eligible provided that the participant has recovered from any acute effects of radiotherapy and is not requiring steroids, and any whole brain radiation therapy was completed at least 2 weeks prior to M7824 administration, or any stereotactic radiosurgery was completed at least 2 weeks prior to M7824 administration.\n* Hepatitis B Virus (HBV) positive participants are eligible-they must have been treated and on a stable dose of antivirals \\[eg, entecavir, tenofovir, or lamivudine; (adefovir or interferon are not allowed)\\] at study entry and with planned monitoring and management according to appropriate labeling guidance.\n* Hepatitis B Virus (HCV) positive participants are eligible if participants are on active HCV therapy at study entry and must be on a stable dose without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling guidance.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to M7824 and\u002For PDS01ADC investigational agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. Participants with a history of bleeding diathesis or recent clinically significant bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded with the exception of hematuria.\n* Participants unwilling to accept blood products as medically indicated\n* Pregnant individuals are excluded from this study because M7824 and\u002For PDS01ADC are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824 and\u002For PDS01ADC, nursing should be discontinued if the nursing individual is treated with these agents.\n* Participants with any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required treatment with either systemic corticosteroids (\\> 10 mg daily prednisone equivalent) or immunosuppressive medications. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Participants with inflammatory bowel disease that have been in remission for at least 5 years whether or not they are currently on immunosuppressive therapy provided that they are not on systemic corticosteroids (\\> 10mg daily prednisone equivalent) are eligible.\n* Participants with any active or recent history of inflammatory bowel disease, active lupus or scleroderma or other medical conditions (i.e., pneumonits with planned SBRT to lung lesion) or genetic radiosensitivity syndromes will be excluded from the study unless deemed eligible by Principal Investigator because these diseases make the participant unsafe or ineligible for radiation therapy with SBRT.\n* Participants with a \"currently active\" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ or incidental organ-confined prostate cancer found on cystoprostatectomy (provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score \\\u003C= 3+4, Prostate-Specific Antigen (PSA) undetectable). Participants are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for \\>= 2 years and currently do not require systemic therapy.\n* Participants having tumor lesion(s) in the liver or chest which are 10 cm or larger.","120 Years",{"count":57,"type":19},100,"INTERVENTIONAL",[60],"PHASE1","Background:\n\nGenitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug PDS01ADC triggers the immune system to fight cancer. Researchers want to learn if these drugs can help fight these cancers when given with and without Stereotactic Body Radiation Therapy (SBRT) radiation.\n\nObjective:\n\nTo learn if M7824 and PDS01ADC, with or without SBRT, can help the immune system to fight cancer better.\n\nEligibility:\n\nPeople 18 and older with cancer that started in the bladder, kidneys, or other genitourinary organs (but not the prostate) and has spread to other parts of the body.\n\nDesign:\n\nParticipants will be screened with:\n\nmedical history\n\nphysical exam\n\nability to do their normal activities\n\nblood tests\n\nurine tests\n\nelectrocardiogram\n\nbody scans.\n\nParticipants will give a tumor sample or have a tumor biopsy.\n\nScreening tests will be repeated during the study.\n\nParticipants will get PDS01ADC . It is injected under the skin every 4 weeks. They will also get M7824 through an intravenous (IV) infusion every 2 weeks. For this, a small plastic tube is put into a vein in the arm. They will get these drugs in 28-day cycles until they leave the study. They may have SBRT.\n\nParticipants will give tissue and saliva samples.\n\nParticipants will have a follow-up visit 30 days after treatment ends. Then they will get phone calls or emails every 12 weeks indefinitely.",[23,24,25,26,27],[64,33,65,66],"Immunocytokine","Urothelial carcinoma","Immune Therapy",{"date":38,"type":39},{"date":69,"type":39},"2020-07-13",{"date":71,"type":19},"2027-12-01",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":82,"conditions":83,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100278638","ontario-wide-cancer-targeted-nucleic-acid-evaluation-100278638","NCT02906943","Ontario-wide Cancer TArgeted Nucleic Acid Evaluation","OCTANE","Inclusion Criteria:\n\n1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.\n2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.\n3. Patient must be ≥ 18 years old.\n4. Patient's ECOG performance status equal to 0 or 1.\n5. All patients must have a life expectancy of \\> 6 months.\n6. All patients must have adequate organ functions.\n7. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent\u002Fmetastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.",{"count":81,"type":19},10000,"Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.\n\nBiomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.\n\nThe study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.\n\nAnother goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.\n\nThe study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.",[84,85,86,87,88,25,89,90,91,92,93],"Breast Cancer","Lung Cancer","Colorectal Cancer","Melanoma","Gynecological Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Cancer",[95,96,97,98,99],"Molecular Profiling","Advanced Cancer","Advanced Solid Tumors","Phase I Clinical Trial Candidates","Next Generation Sequencing","2026-06-03",{"date":38,"type":39},{"date":103,"type":4},"2016-08",{"date":105,"type":19},"2027-08",{"name":107,"class":108},"University Health Network, Toronto","OTHER",7,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240","NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.\n2. Prior allogeneic stem cell transplant",{"count":118,"type":19},7000,"This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[84,85,87,121,25,89,90,91,92,122],"Gynecologic Cancer","Unknown Primary Tumors",[124,125,126],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","2026-05-06",{"date":129,"type":39},"2026-05-11",{"date":131,"type":39},"2026-03-31",{"date":133,"type":19},"2031-03-31",{"name":107,"class":108},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":58,"phases":144,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100622892","early-phase-1-immune-checkpoint-inhibitor-ici-drug-drug-interaction-ddi-study-100622892","NCT07389525","Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Inclusion Criteria:\n\n* ≥ 18 years old at the time of informed consent\n* Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)\n* Ability to provide written informed consent and HIPAA authorization\n\nExclusion Criteria:\n\n* Actively pregnant or breastfeeding\n* Body weight less than 50 kg or a BMI \\>35\n* Low baseline hemoglobin, defined as \\\u003C10 g\u002FdL\n\n  * Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)\n* Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase \\>96 U\u002FL, alanine aminotransferase \\> 80 IU\u002FL, alkaline phosphatase \\>260 U\u002FL, or total bilirubin \\> 2.6 mg\u002FdL\n\n  * Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)\n* Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate \\\u003C45 mL\u002Fminute\u002F1.73 m2 BSA\n\n  * Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)\n* Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)\n* Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis\n* History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)\n* Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)\n* Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Concomitant treatment with a CYP\u002Ftransporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Are unwilling\u002Funable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study\n* Inability to take oral medication",{"count":143,"type":19},80,[145],"EARLY_PHASE1","Immune checkpoint inhibitors (ICIs) (also called \"immunotherapy\") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.",[148,25,149,150,87],"Gastrointestinal Neoplasms","Thoracic Cancer","Sarcoma",[152,153],"cytokines","immune checkpoint inhibitor","NOT_YET_RECRUITING","2026-04-21",{"date":157,"type":39},"2026-04-24",{"date":159,"type":19},"2026-06",{"date":161,"type":19},"2027-12",{"name":163,"class":108},"Indiana University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":58,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100627316","phase-2-riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial-100627316","NCT07447050","Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)","Inclusion Criteria:\n\n* Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen.\n* ≥18 years of age.\n* Life expectancy \\> 6 months\n* Able to provide informed consent.\n* Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n* Presence of primary brain tumors or brain metastases.\n* Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.\n* Unwilling to undergo neuropsychological assessments necessary for the study.\n* Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* History of or suspected hypersensitivity to riluzole or to any of its excipients.\n* Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n* Hepatic impairment as indicated by: AST and\u002For ALT ≥ 3 X upper limit normal (ULN).\n* Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":172,"type":19},24,[174],"PHASE2","This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.",[84,150,177,85,91,86,178,179,25,121],"Gastric (Stomach) Cancer","Ovarian Cancer","Liver Cancer","2026-02-25",{"date":182,"type":39},"2026-03-03",{"date":184,"type":39},"2025-12-23",{"date":186,"type":19},"2028-12-31",{"name":188,"class":108},"University of California, Irvine",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":47},"100389683","circulating-tumor-dna-ctdna-for-early-treatment-response-assessment-of-solid-tumors-100389683","NCT04354064","Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors","Inclusion Criteria:\n\n* Eligible healthy donors will be at least 18 years of age.\n\nExclusion Criteria:\n\n* Healthy donors younger than 18 years of age",true,{"count":57,"type":19},"Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.",[199,200,91,201,25,150,84,202,90,203,85,204,87],"Healthy Volunteer","Prostate Cancer","Esophageal Cancer","Colon Cancer","Solid Tumor Cancer","Skin Cancer","2026-02-17",{"date":207,"type":39},"2026-02-20",{"date":209,"type":39},"2019-05-29",{"date":211,"type":19},"2026-12-31",{"name":213,"class":108},"Washington University School of Medicine",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":47},"100577191","discharge-medication-use-post-operatively-in-gu-cancer-patients-100577191","NCT06795087","Discharge Medication Use Post-Operatively in GU Cancer Patients","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information.\n2. Age ≥ 18 years at the time of enrollment\n3. Scheduled to undergo surgical cystectomy, partial or total nephrectomy or prostatectomy for a cancer diagnosis.\n4. Ability to read and understand the English and\u002For Spanish language.\n5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* None",{"count":221,"type":19},684,"The main purpose of this research study is to determine the amount of opioids that are taken after discharge following a cystectomy, nephrectomy (partial or total), or prostatectomy surgeries via a 30-day post- discharge opioid use and disposal survey. We will also evaluate the impact of an opioid disposal education pamphlet on proper disposal of unused opioids.",[25],[25,225,226,227],"Cystectomies","Nephrectomies","Prostatectomies","2026-01-20",{"date":230,"type":39},"2026-01-22",{"date":232,"type":39},"2025-02-21",{"date":234,"type":19},"2027-07",{"name":236,"class":108},"Wake Forest University Health Sciences",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":58,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100383469","phase-2-investigating-the-effects-of-atezolizumab-in-people-whose-tumour-dna-or-rna-indicates-possible-sensitivity-100383469","NCT04273061","Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention","CAPTIV-8","Inclusion Criteria:\n\n* Age greater than or equal to 18 years at the time of signature of informed consent.\n* Participants with an incurable solid tumour who have undergone whole genome and transcriptome analysis (WGTA) as part of Personalized OncoGenomics (POG) or equivalent program.\n\n  a. Participants must have had successful sequencing of their tumour, been formally reviewed by the POG (or POG-approved) genome analysts and found to have CAPTIV-8 factors identified (including Immune, Burden, Variant (IBV) score ≥ 5), been reviewed at the Molecular Tumour Board (MTB) (or site equivalent), and allocated to a specific tumour-defined cohort (that is open for enrolment) with a final opinion documented.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Participants must have measurable disease, as defined by RECIST 1.1.\n* Life expectancy of at least 12 weeks.\n* Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 28 days prior to the first study treatment:\n\n  1. Absolute neutrophil count (ANC) ≥ 1500 cells\u002FµL without granulocyte colony- stimulating factor support.\n  2. White blood cell (WBC) counts \\> 2500\u002FµL.\n  3. Lymphocyte count ≥ 500\u002FµL.\n  4. Serum albumin ≥ 2.5 g\u002FdL.\n  5. Platelet count ≥ 100,000\u002FµL without transfusion (without transfusion within 2 weeks of laboratory test used to determine eligibility).\n  6. Hemoglobin ≥ 9.0 g\u002FdL, participants may be transfused or receive erythropoietic treatment to meet this criterion.\n  7. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 × Upper Limit of Normal (ULN). This applies only to participants who are not receiving therapeutic anticoagulation; participants receiving therapeutic anticoagulation must have an INR or aPTT within therapeutic limits for at least 1 week prior to enrolment.\n  8. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN with the following exceptions: i) Participants with documented liver metastases: AST and\u002For ALT ≤ 5 × ULN. ii) Participants with documented liver or bone metastases: ALP ≤ 5 × ULN.\n  9. Serum bilirubin ≤ 1.5 × ULN. Participants with known Gilbert's syndrome who have serum bilirubin level ≤ 3 × ULN may be enrolled.\n  10. Serum creatinine ≤ 1.5 × ULN.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% (one percent) per year during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse with a female partner of childbearing potential or who is pregnant) or use contraceptive measures that result in a failure rate of less than 1% (one percent) per year, and agreement to refrain from donating sperm, during the treatment period and for at least 5 months after the last dose of atezolizumab.\n* Asymptomatic participants with treated or untreated CNS lesions are eligible provided that all of the following criteria are met:\n\n  1. Measurable disease, per RECIST 1.1, must be present.\n  2. The participant has no history of intracranial hemorrhage or spinal cord hemorrhage.\n  3. The participant has not undergone stereotactic radiotherapy within 7 days prior to the initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.\n  4. The participant has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted.\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Any prior treatment with monoclonal antibodies targeting the Programmed Death 1\u002FLigand (PD-1\u002FPD-L1) axis, including antibody-drug conjugates and other experimental agents.\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days or five half-lives of the drug, whichever is longer, prior to enrollment. Participants receiving gonadotropin releasing hormone (GnRH) analogues may continue to receive treatment while participating in CAPTIV-8.\n* Pregnancy or breastfeeding.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.\n* Active autoimmune disease at any point within the last 2 years prior to enrollment including but not limited to:\n\n  1. Myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n  2. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible for this study.\n  3. Participants with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study.\n* Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., participants with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n  1. Rash must cover less than 10% (ten percent) of body surface area (BSA).\n  2. Disease is well controlled at baseline and only requiring low potency topical steroids.\n  3. No acute exacerbations of underlying condition within the last 12 months requiring treatment with either psoralen plus ultraviolet radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors or high potency or oral steroids.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for HIV (participants with a history of\u002For symptoms of HIV are eligible only if serological tests are negative).\n* Participants with hepatitis B virus (HBV) are excluded if one of the following conditions is met:\n\n  1. Positive hepatitis B surface antigen (HBsAg) test at screening; or\n  2. Negative or positive hepatitis B surface antibody (HBsAb) test at screening accompanied by a positive total hepatitis B core antibody (HBcAb) test followed by a positive (per local laboratory definition) HBV DNA test.\n* Positive hepatitis C virus (HCV) antibody test followed by a positive HCV RNA test at screening.\n* Active tuberculosis.\n* Severe infections within 2 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.\n* Major surgical procedure within 21 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.\n* Prior allogeneic stem cell or solid organ transplant.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2 (IL-2)) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumour necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Participants who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.",{"count":246,"type":19},200,[174],"This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer.\n\nThis is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.",[84,85,90,25,121,150,122,91,204],[251,252,253,254,255,256,257,258],"Genomic analysis","Atezolizumab","Whole genome and transcriptome analysis","Immune Burden Variant score","Immune checkpoint inhibition","Personalized OncoGenomics","Phase 2","Precision targeting","2025-09-17",{"date":261,"type":39},"2025-09-22",{"date":263,"type":39},"2020-06-17",{"date":265,"type":19},"2027-10",{"name":267,"class":108},"British Columbia Cancer Agency",2,{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":58,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":47},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n* Female and male patients diagnosed with one of the following:\n\n  1. Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions\n  2. Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years\n  3. Non-breast cancer patients exposed to other anticancer therapies within the past 3 years\n* Washout from investigational interventions is up to the discretion of the Investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n* ≥18 years of age\n* Perceived by patient or investigator that cognitive function has worsened since cancer diagnosis and\u002For beginning of cancer treatment\n* Able to provide informed consent.\n* Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n* Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\nNote: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n* Presence of brain metastasis\n* Unwilling to undergo neuropsychological assessments necessary for the study.\n* Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n  a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* History of suspected hypersensitivity to riluzole or to any of its excipients.\n* Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n* Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n* Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":277,"type":19},51,[174],"This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.",[84,150,281,85,91,86,178,179,25,121],"Gastric Cancer","2025-06-21",{"date":284,"type":39},"2025-06-26",{"date":286,"type":39},"2024-12-02",{"date":161,"type":19},{"name":188,"class":108},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":58,"phases":298,"briefSummary":300,"conditions":301,"keywords":312,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":47},"100580294","high-resolution-pet-ct-specimen-imaging-for-the-perioperative-visualization-of-resection-margins-100580294","NCT06835426","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins: an Exploratory Pilot Study","A. Inclusion Criteria:\n\n* able to understand treatment protocol and informed consent form\n* estimated by the investigator to be compliant for study participation\n\n  1\\. Fulfilling all group-specific inclusion criteria:\n* confirmed breast cancer with an indication to undergo breast conserving surgery\n* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;\n* confirmed thyroid lesion with an indication to undergo resective surgery;\n* confirmed parathyroid adenoma with an indication to undergo resective surgery;\n* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;\n* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;\n* suspected lesion in the head \\& neck region with an indication to undergo resective surgery;\n* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;\n* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.\n* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.\n* suspected brain tumor with an indication to undergo resective surgery.\n* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.\n* suspected malignant thoracovascular lesions with an indication to undergo resective surgery\n\nB. Exclusion Criteria:\n\n* general or local contra-indications for resective surgery;\n* in case of FDG-based PET tracers: a blood glucose level over 200 mg\u002FdL on the day of surgery;\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.",{"count":297,"type":19},150,[299],"NA","These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.\n\nPositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.\n\nThe overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.",[302,303,304,305,204,25,91,306,307,308,309,310,311],"Breast Carcinoma","Prostate Cancer Surgery","Thyroid Cancer","Parathyroid Adenomas","Hepatobiliary Cancers","Metabolic Abnormality","Neuro Endocrine Tumours","Brain Tumours","Gastro Intestinal Cancer","Thoracoscopic Surgery",[313,314,315,316,317,318,319,320,321,322],"resective surgery","perioperative high-resolution PET-CT specimen imaging","breast cancer","Prostate cancer","thyroid cancer","parathyroid cancer","head and neck cancer","neuro-endocrine malignancies","genitourinary malignacies","thoracovascular malignancies","2025-02-14",{"date":325,"type":39},"2025-02-19",{"date":327,"type":39},"2023-08-06",{"date":329,"type":19},"2027-06-30",{"name":331,"class":108},"Algemeen Ziekenhuis Maria Middelares",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":340,"conditions":341,"keywords":348,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":47},"100342582","genomic-investigation-of-unusual-responders-100342582","NCT03740503","Genomic Investigation of Unusual Responders","GENIUS","Inclusion Criteria:\n\n1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.\n\n   1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months\n   2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)\n2. The patient must have sufficient archival tumor available for sequencing.\n3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:\n\n   a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.\n\n   b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program\n\n   Exclusion Criteria:\n   * None",{"count":57,"type":19},"Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and\u002For other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.",[342,84,343,86,25,88,344,345,346,92,347],"Cancer","Non-small Cell Lung Cancer","Upper Aerodigestive Tract Cancer","Pancreatobiliary Gastrointestinal Cancer","Melanoma (Skin)","Carcinoma of Unknown Primary",[342,84,349,86,25,88,344,345,350,92,93],"Non- small Cell Lung Cancer","Melanoma Cancer","2025-01-30",{"date":353,"type":39},"2025-01-31",{"date":355,"type":39},"2013-11-01",{"date":357,"type":19},"2025-11",{"name":107,"class":108}]